Semaglutide (Sema G) PEN 2 mg

One-Peptides SEMA G PEN 2 mg – pre-dissolved pen for laboratory research

SEMA G PEN 2 mg is a research reagent (Research Use Only) in the form of a pre-dissolved pen. The active substance – GLP-1 – is also present on the market as an EMA- and FDA-registered medicine, including in pen format. These two occurrences of the same peptide belong to two separate regulatory frameworks: the RUO pen in the One Peptides catalogue is not a medicine, is not intended for human use and is not regulated as a pharmaceutical product. The RUO pen belongs to the chemical-reagent market. Identity of the active substance does not remove that boundary.

Semaglutide is one of the best clinically documented peptides of the last decade: a GLP-1 receptor monoagonist that underpins the modern landscape of incretin pharmacology. Reference literature includes the SUSTAIN program (type 2 diabetes) and STEP program (obesity), with endpoints reported in NEJM and The Lancet. The molecule was developed by Novo Nordisk, which holds the registrations for Ozempic, Wegovy and Rybelsus. A full overview of the clinical literature is available in the article on semaglutide and what we know from clinical trials.

In the One Peptides catalogue, the same peptide appears in a separate regulatory frame: as an RUO research reagent in a pre-dissolved pen format. This format simplifies laboratory work because it does not require lyophilizate reconstitution and allows precise peptide sampling under controlled conditions. It is a technical solution for researchers working with semaglutide in in vitro and in vivo models – not a medicinal dosage form and not a therapeutic analogue for human administration. The full context of incretin peptides is described in the guide to GLP-1 peptides in metabolic research.

What is Sema G Pen – sequence and class

Semaglutide is a GLP-1 receptor (GLP-1R) monoagonist: a stabilized analogue of endogenous glucagon-like peptide-1. The molecule contains 31 amino acids and has a molecular mass of approximately 4113 Da. Compared with human GLP-1, structural modifications were introduced to stabilize the peptide against enzymatic degradation and prolong its half-life.

The informal shorthand used for retatrutide in online searches is explained in a separate entry: what “reta” means in informal usage.

C18 fatty-acid acylation enables reversible binding to serum albumin. Albumin acts as a reservoir: the molecule circulates partly bound, is gradually released and then degraded. The effect is a serum half-life of approximately 7 days (weekly schedule in Ozempic and Wegovy protocols).

Chemical characteristics

Mechanism of action in research

Activation of the GLP-1 receptor triggers a cascade of four complementary effects reported in clinical and preclinical literature. The full physiology of the incretin axis is discussed in the article on GLP-1, GIP and glucagon incretins.

Glucose-dependent insulin secretion. In pancreatic beta cells, activation of the G-protein-coupled GLP-1R increases cAMP levels, potentiating insulin release in response to glucose load. The mechanism is glucose-dependent: under normoglycemia, insulin secretion is not significantly stimulated.

Postprandial inhibition of glucagon secretion in pancreatic alpha cells – together with insulin stimulation, this provides two-point control of postprandial glycemia.

Central action – appetite modulation. GLP-1R in the arcuate nucleus of the hypothalamus mediates satiety signaling. Delayed gastric emptying further extends post-meal satiety.

Reference data come from Novo Nordisk research programs: SUSTAIN (Marso et al. 2016, SUSTAIN-6 – cardiovascular endpoints in type 2 diabetes) and STEP (Wilding et al. 2021, STEP-1 – obesity). In STEP-1, mean body-weight reduction of approximately 14.9% was reported after 68 weeks of semaglutide 2.4 mg once weekly vs placebo.

Sema G Pen RUO vs pharmaceutical pen (Ozempic, Wegovy) – fundamental difference

The active substance is the same (semaglutide), but the products belong to two separate regulatory lines with different documentation and intended use. Novo Nordisk’s pen is a medicinal product with a patient leaflet, SmPC and EMA pharmacovigilance oversight. The RUO pen in the One Peptides catalogue is a chemical reagent with analytical documentation (COA, HPLC, MS). Identity of the peptide does not remove the regulatory distinction.

Applications in scientific research

Sema G Pen as an RUO reagent can be used in several research directions.

Pharmacology of the GLP-1 axis. Receptor-activity analysis, GLP-1R selectivity profiling, EC50 measurements in cell cultures with cAMP and beta-arrestin reporters. The pen format supports precise solution sampling for serial dilutions.

Animal models of insulin resistance and obesity. DIO mice, ob/ob and db/db models, Zucker rats. Endpoints: body weight, body composition (DEXA, NMR), OGTT/ITT, HOMA-IR and lipid profile. Semaglutide functions as a reference GLP-1R monoagonist for comparison with newer analogues.

Pharmacokinetics and central effects on appetite. PK profile of acylated GLP-1 analogues, albumin-binding kinetics, behavioral satiety models and activation of POMC neurons in the arcuate nucleus.

Comparative analyses with other GLP-1 analogues – liraglutide, dulaglutide, exenatide, tirzepatide (dual GLP-1R/GIPR), retatrutide (triple GLP-1R/GIPR/GCGR agonist). Semaglutide is a reference monoagonist for SAR work. A direct comparison with retatrutide is available in the comparison of mechanisms and clinical outcomes.

One Peptides quality specification

Every Sema G pen passes a five-stage analytical control process.

• HPLC >=98% – the main peak area is >=98% of total area (liquid chromatography with UV detection).
• MS confirmation – peptide identity confirmed by molecular mass (~4113 Da).
• COA per batch – public certificate of analysis for each batch (theoretical/measured mass, HPLC profile, synthesis date, batch number).
• Cold chain 2-8°C – monitored cold-chain handling from synthesis to delivery.
• Batch traceability – batch number in three places: pen label, invoice, COA.

Details of the QA process, example COAs and a description of each of the five control stages are available under quality testing and certificates.

Working with a pre-dissolved pen in a laboratory protocol

The following guide describes technical handling of the pen in the context of a laboratory research reagent. It is not an instruction for administration to humans or animals; an RUO pen is not a pharmaceutical injection form for humans. The pen format is technical: it provides a stable, pre-dissolved peptide source for further experimental work.

Pen content. Sema G Pen 2 mg contains 2 mg of pre-dissolved semaglutide in typically 1.5 mL of solution (configuration may vary depending on the batch; details are in the COA).

Working with the pen. A full step-by-step guide for lyophilizates is available in the article how to dissolve peptides; the pen eliminates this stage. Bacteriostatic water is typically relevant only in the context of further serial dilutions. Sampling is performed with a laboratory syringe or dosing applicator with microliter precision. The solution should be clear; cloudiness, sediment or color change indicates that the batch is not suitable for further work.

Working solutions. For in vitro receptor assays, picomolar to nanomolar ranges are typically used. Working solutions are prepared through serial dilutions in PBS at pH 7.4 or buffers compatible with the specific experimental system.

Stability. Unopened pen: typically up to 24 months at 2-8°C, protected from light (details in the COA). After first opening: typically up to 28 days at 2-8°C. Avoid freeze-thaw cycles; acylated peptides are sensitive to thermal denaturation.

The peptide calculator helps convert the starting concentration from the pen into the desired working concentration when planning serial dilutions.

This is not an instruction for administration to humans. Clinical semaglutide schedules (Ozempic, Wegovy) described in SmPC documents apply only to medicines registered by Novo Nordisk, not to research reagents.

Regulatory status – Sema G Pen, Ozempic, Wegovy

Sema G Pen (this product) is a Research Use Only reagent in the EU chemical-reagent market. Label: “For research use only. Not for human use”. It is not a medicinal product, dietary supplement or food product. It has no EMA or FDA authorization as a medicine.

Semaglutide as a medicine (Novo Nordisk): Ozempic – injectable pen, type 2 diabetes (FDA 2017, EMA 2018); Wegovy – injectable pen, obesity (FDA 2021, EMA 2022); Rybelsus – oral form, type 2 diabetes (FDA 2019).

Only medicines registered by Novo Nordisk have medicinal-product status. Sema G Pen RUO does not. Identity of the active substance (semaglutide) does not remove this distinction.

WADA. GLP-1 agonist peptides are not directly listed as a separate category on the current WADA Prohibited List. Status may change in future editions; verification of current guidelines rests with the researcher.

Frequently asked questions

How does Sema G Pen RUO differ from Ozempic / Wegovy?

The active substance is the same: semaglutide. The difference is the regulatory framework. Sema G Pen is a Research Use Only reagent with analytical documentation (COA, HPLC, MS). Ozempic and Wegovy are Novo Nordisk medicines with full EMA/FDA registration documentation, available only by prescription under medical supervision. The RUO pen is not a medicinal dosage form.

Is Sema G Pen a weight-loss medicine?

No. It is an RUO reagent for laboratory research. The registered medicine in the EU for obesity is Wegovy (Novo Nordisk), and only that product is regulated as a pharmaceutical therapy.

Can Sema G Pen be used like Ozempic?

No. The RUO pen is not regulated as a pharmaceutical product and does not have a pharmaceutical quality profile (GMP, injection sterility, endotoxin control at levels required for medicines). It has analytical reagent documentation, not medicinal-product documentation. Clinical semaglutide schedules from the Ozempic and Wegovy SmPC apply only to Novo Nordisk medicines.

How long does the pen retain activity after first opening?

Typically up to 28 days at 2-8°C from first sampling. Specific stability data are provided in the batch COA. Avoid freeze-thaw cycles.

Does Sema G Pen require reconstitution?

No. The pen format is a pre-dissolved semaglutide solution, ready for sampling with a syringe or applicator, without adding solvent. This is the fundamental difference from lyophilized vials.

Is semaglutide on the WADA list?

The current WADA Prohibited List does not directly list GLP-1 agonists as a separate category. Status may change; verification of the guidelines rests with the researcher.

References

1. Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity
2. Marso SP et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
3. Davies M et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
4. Frias JP et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
5. Lau J et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

Research Use Only chemical reagent. Sema G Pen 2 mg in the One Peptides catalogue is not a medicinal product, dietary supplement or food product. It is not intended for administration to humans or animals outside a controlled experimental environment. Do not confuse Sema G Pen RUO with semaglutide medicines registered by Novo Nordisk: Ozempic, Wegovy, Rybelsus. The active substance is the same (semaglutide), but the RUO pen and pharmaceutical pen belong to two separate regulatory frameworks with different documentation and intended use. The information in this description is educational and scientific and refers to findings reported in the literature; it is not medical advice or administration instruction.